Galectin-3 and mineralocorticoid receptor antagonist use in patients with chronic heart failure due to left ventricular systolic dysfunction
Gandhi PU, Motiwala SR, Belcher AM, Gaggin HK, Weiner RB, Baggish AL, Fiuzat M, Rocca H, Januzzi JL. Galectin-3 and mineralocorticoid receptor antagonist use in patients with chronic heart failure due to left ventricular systolic dysfunction. American Heart Journal 2015, 169: 404-411.e3. PMID: 25728731, DOI: 10.1016/j.ahj.2014.12.012.Peer-Reviewed Original ResearchConceptsElevated galectin-3Mineralocorticoid receptor antagonistsCV event ratesMRA therapyGalectin-3 concentrationsQuality of lifeGalectin-3CV eventsHeart failureMRA useLeft ventricular systolic dysfunctionMineralocorticoid receptor antagonist useTreatment-related adverse eventsEvent ratesBaseline galectin-3Ventricular remodeling indexChronic heart failureOutcomes of patientsReduced ejection fractionVentricular systolic dysfunctionReceptor antagonist useSignificant renal dysfunctionFirst CV eventHeart failure biomarkersChronic HFrEF